Chronic kidney disease Market Key Highlights and Future Opportunities Till 2035
The global chronic kidney disease (CKD) market is projected to grow significantly, with a valuation of USD 38.91 billion in 2024 expected to reach USD 67.36 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.12% during this period. This growth is driven by the increasing prevalence of CKD worldwide, fueled by factors such as unhealthy dietary habits, sedentary lifestyles, and the rising incidence of related conditions like hypertension and diabetes[2].
Market Drivers and Trends
The expanding CKD patient population, coupled with technological advancements in diagnostics and therapeutics, is a key market driver. Efforts to develop advanced therapeutic drugs and early diagnostic tools, including biomarkers and molecular diagnostics, are gaining momentum. Precision medicine, including genetic profiling, is becoming increasingly important due to the heterogeneous nature of CKD. Additionally, innovations such as 3D kidney microphysiological systems and 3D bioprinting by companies like AstraZeneca, as well as the use of artificial intelligence and big data analytics for early diagnosis, are shaping the market landscape[2].
Market Segmentation
The CKD market is segmented by drug class, molecule type, treatment type, disease indication, route of administration, end user, and geography:
- Drug Class: ACE inhibitors hold the largest market share (~25%) as they are the first-line treatment for many CKD types, including hypertensive and diabetic nephropathy, and help slow disease progression by reducing proteinuria. Erythropoiesis-stimulating agents (ESAs) are also significant due to their role in treating anemia caused by reduced erythropoietin production in CKD patients. Other drug classes include angiotensin-II receptor blockers, calcium channel blockers, beta blockers, diuretics, and emerging cell therapies aimed at preventing dialysis[2].
- Type of Molecule: Small molecules dominate the market due to their ability to reach intracellular targets easily. However, biologics, such as monoclonal antibodies, are expected to grow at a higher CAGR because of their high specificity and stability, making them suitable for targeted therapies[2].
- Type of Treatment: The drug segment currently holds the majority share, supported by government funding and research initiatives aimed at slowing disease progression. Dialysis and kidney transplant segments also contribute, with dialysis centers expected to grow rapidly due to increasing patient needs and efforts to improve access, exemplified by companies like VitusCare Medlife in India[2].
- Disease Indication: Diabetic nephropathy accounts for the largest market share, driven by the global diabetes epidemic. Other indications include glomerulonephritis, hypertensive nephropathy, and polycystic kidney disease[2].
- Route of Administration: Oral administration dominates (~60%) due to convenience and preference among geriatric patients. Parenteral routes are anticipated to grow faster, driven by targeted therapies delivered intravenously or subcutaneously[2].
- End User: Hospitals and clinics hold the largest market share because of their comprehensive treatment capabilities and advanced technologies. Dialysis centers are expected to grow rapidly as more patients require frequent dialysis outside hospital settings[2].
- Geographical Regions: North America currently leads the market, supported by high CKD prevalence and substantial healthcare investments. The Asia-Pacific region is forecasted to grow at the highest CAGR, propelled by increasing research, government initiatives, and rising healthcare quality demands[2].
Challenges
Market growth faces challenges such as complex regulatory guidelines, high initial investments for drug development and diagnostics, and adverse side effects of existing therapies. High costs of dialysis and treatments can limit patient access, especially in developing countries. Late diagnosis also hampers treatment effectiveness. For example, the cost of some drugs like Akebia’s Vafseo® is relatively high, which may restrict uptake[2].
Key Players and Recent Developments
Leading companies in the CKD market include AbbVie, Amgen, Abbott, AstraZeneca, Akebia Therapeutics, Bristol-Myers Squibb, Fresenius Medical Care, FibroGen, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi, Siemens Healthcare, and Teva Pharmaceutical Industries[2]. Startups such as Klotho Therapeutics and ProKidney are also innovating in this space.
URL:
https://www.rootsanalysis.com/reports/chronic-kidney-disease-market/235.html Chronic kidney disease Market Key Highlights and Future Opportunities Till 2035
The global chronic kidney disease (CKD) market is projected to grow significantly, with a valuation of USD 38.91 billion in 2024 expected to reach USD 67.36 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.12% during this period. This growth is driven by the increasing prevalence of CKD worldwide, fueled by factors such as unhealthy dietary habits, sedentary lifestyles, and the rising incidence of related conditions like hypertension and diabetes[2].
Market Drivers and Trends
The expanding CKD patient population, coupled with technological advancements in diagnostics and therapeutics, is a key market driver. Efforts to develop advanced therapeutic drugs and early diagnostic tools, including biomarkers and molecular diagnostics, are gaining momentum. Precision medicine, including genetic profiling, is becoming increasingly important due to the heterogeneous nature of CKD. Additionally, innovations such as 3D kidney microphysiological systems and 3D bioprinting by companies like AstraZeneca, as well as the use of artificial intelligence and big data analytics for early diagnosis, are shaping the market landscape[2].
Market Segmentation
The CKD market is segmented by drug class, molecule type, treatment type, disease indication, route of administration, end user, and geography:
- Drug Class: ACE inhibitors hold the largest market share (~25%) as they are the first-line treatment for many CKD types, including hypertensive and diabetic nephropathy, and help slow disease progression by reducing proteinuria. Erythropoiesis-stimulating agents (ESAs) are also significant due to their role in treating anemia caused by reduced erythropoietin production in CKD patients. Other drug classes include angiotensin-II receptor blockers, calcium channel blockers, beta blockers, diuretics, and emerging cell therapies aimed at preventing dialysis[2].
- Type of Molecule: Small molecules dominate the market due to their ability to reach intracellular targets easily. However, biologics, such as monoclonal antibodies, are expected to grow at a higher CAGR because of their high specificity and stability, making them suitable for targeted therapies[2].
- Type of Treatment: The drug segment currently holds the majority share, supported by government funding and research initiatives aimed at slowing disease progression. Dialysis and kidney transplant segments also contribute, with dialysis centers expected to grow rapidly due to increasing patient needs and efforts to improve access, exemplified by companies like VitusCare Medlife in India[2].
- Disease Indication: Diabetic nephropathy accounts for the largest market share, driven by the global diabetes epidemic. Other indications include glomerulonephritis, hypertensive nephropathy, and polycystic kidney disease[2].
- Route of Administration: Oral administration dominates (~60%) due to convenience and preference among geriatric patients. Parenteral routes are anticipated to grow faster, driven by targeted therapies delivered intravenously or subcutaneously[2].
- End User: Hospitals and clinics hold the largest market share because of their comprehensive treatment capabilities and advanced technologies. Dialysis centers are expected to grow rapidly as more patients require frequent dialysis outside hospital settings[2].
- Geographical Regions: North America currently leads the market, supported by high CKD prevalence and substantial healthcare investments. The Asia-Pacific region is forecasted to grow at the highest CAGR, propelled by increasing research, government initiatives, and rising healthcare quality demands[2].
Challenges
Market growth faces challenges such as complex regulatory guidelines, high initial investments for drug development and diagnostics, and adverse side effects of existing therapies. High costs of dialysis and treatments can limit patient access, especially in developing countries. Late diagnosis also hampers treatment effectiveness. For example, the cost of some drugs like Akebia’s Vafseo® is relatively high, which may restrict uptake[2].
Key Players and Recent Developments
Leading companies in the CKD market include AbbVie, Amgen, Abbott, AstraZeneca, Akebia Therapeutics, Bristol-Myers Squibb, Fresenius Medical Care, FibroGen, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi, Siemens Healthcare, and Teva Pharmaceutical Industries[2]. Startups such as Klotho Therapeutics and ProKidney are also innovating in this space.
URL: https://www.rootsanalysis.com/reports/chronic-kidney-disease-market/235.html
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)